Insider Transactions

Directors' and officers' dealings in more than fifty markets, read from the official source in each one.

When the people who run a company buy its stock with their own money, it is worth knowing. ORTEX reads directors' and officers' dealings from official regulator and exchange sources across more than fifty markets, 7.2 million transactions in all, and scores every one for conviction. You can separate a deliberate open-market purchase from a routine grant at a glance, anywhere in the world, in one feed.

At a glance

  • 7.2m insider transactions from official sources
  • 50+ markets covered
  • 237,000 insiders profiled
  • < 1 min from SEC publication to the ORTEX feed

1.6x as many insider trading days as the leading global aggregator in our own 12-month comparison, because ORTEX reads the regulators directly in more than fifty markets rather than relying on one resold feed.

ORTEX comparison, trailing 12 months to September 2026.

What you can do with it

  • Idea generation. Cluster buys and large open-market purchases by executives, within a minute of filing.
  • Systematic signals. Decades of point-in-time filings across markets to build and test an insider factor.
  • Monitoring. Follow a person, a board or a whole market in one consistent feed.

Global coverage, scored for conviction

One feed across more than fifty markets, and a score you can rank across all of them.

  • Europe and the UK. The UK and every major European market, from Germany, France and the Nordics to Poland, Greece, the Baltics and Turkey.
  • Asia-Pacific. Korea, China, Hong Kong, India, Singapore, Malaysia, Thailand, Indonesia, Vietnam, the Philippines, Australia and New Zealand.
  • Americas, Middle East and Africa. The US, Canada, Brazil, Chile, Israel, South Africa, Egypt and more.
  • Conviction, scored. Every trade carries a 0 to 3 conviction score. A discretionary open-market purchase scores top; a grant, a vesting or a tax withholding scores low.
  • People, not just filings. 237,000 insiders profiled with their full history across every company, and 42,000 rated on how their past trades performed.
  • Within a minute. US filings are in the feed within a minute of the SEC publishing them, and every other market is collected continuously as its regulator publishes. Canada from 1995, the UK from 1999.

Facts

Coverage50+ markets, official regulator and exchange sources
Scale7.2m transactions: 5.74m global plus 1.47m US
HistoryDecades in most markets; Canada from 1995
SpeedUS within a minute of SEC publication; others continuously
DeliveryAPI, CSV, ORTEX platform

Why ORTEX

Most global insider feeds are resold from one aggregator. ORTEX reads the regulators directly in more than fifty markets, which in our comparison produced 1.6 times as many trading days, and every row states whether it carries a share count, a value or both, so markets compare like with like.

Insider buying, as filed

Recent top-conviction purchases by board members in Europe, straight from each national regulator.

Selected open-market purchases, October and November 2026

PublishedMarketCompanyInsiderRoleSharesPriceConviction
26 Oct 2026SwedenSvenska HandelsbankenFredrik LundbergBoard member1,000,000SEK 148.003 of 3
21 Oct 2026DenmarkDSVJens H. LundGroup CEO7,779DKK 1,279.823 of 3
2 Nov 2026NorwayScatecFinn Bjørn RuyterBoard member20,000NOK 84.203 of 3
30 Oct 2026FinlandKONETimo IhamuotilaBoard member6,245EUR 54.913 of 3
27 Oct 2026UKIG GroupBreon CorcoranCEO30,000GBP 9.453 of 3

Every row links back to the original regulatory filing.

SourceEach national regulator or exchange
Score0 to 3 conviction on every trade
ProfileFull history for every insider across companies

A board member buying a million shares with their own money is a different signal from a scheduled vesting, and the score says so.

Documents and API

Coverage, history and figures are as at November 2026. Provided for information purposes only; not investment advice, a personal recommendation, or an offer to buy or sell any security. Past performance is not a guide to future results. Trial access, pricing and licensing: [email protected].


Did this page help you?